<DOC>
	<DOCNO>NCT01395667</DOCNO>
	<brief_summary>In phase I trial neoadjuvant CCRT combine IMRT three escalate dose level ( 45 Gy , 50 Gy , 55 Gy 25 fraction ) BV-fluorouracil/ leucovorin/oxaliplatin ( FOLFOX ) regimens planned 15 locally advanced rectal cancer patient . The primary goal define maximally tolerate dose radiotherapy treatment relate acute toxicity , demonstrate preoperative highly conformal IMRT concurrent BV-chemotherapy lead acceptable acute gastrointestinal morbidity . The secondary goal demonstrate treatment modality elicit comparable improve rate T stage downstaging complete response pathologically .</brief_summary>
	<brief_title>Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy Combination With Bevacizumab-FOLFOX</brief_title>
	<detailed_description>Rectal cancer one lead cancer Taiwan country world . Preoperative neoadjuvant concurrent chemoradiotherapy ( CCRT ) well accept widely use modality locally advanced rectal cancer , improve local control , reduce treatment related toxicity , increase anal preservation rate . Intensity modulate radiation therapy ( IMRT ) , common advance technique recent 10 year , proven effective dose escalation , treatment target conformity , normal tissue spar . The ongoing trial rectal cancer increasingly adopt IMRT treatment technique . Bevacizumab ( BV ) , develop drug target vascular endothelial growth factor , proven effective use metastatic colorectal cancer . Besides , BV show good radiosensitizing effect evolve neoadjuvant CCRT trial use traditional big-field pelvis radiotherapy rectal cancer , ongoing brain tumor trial , basic research . Neoadjuvant CCRT use combination IMRT BV may dual advantage reduce treatment toxicity technique increase pathological response radiosensitization possible improve outcome . In phase I trial neoadjuvant CCRT combine IMRT three escalate dose level ( 45 Gy , 50 Gy , 55 Gy 25 fraction ) BV-fluorouracil/ leucovorin/oxaliplatin ( FOLFOX ) regimens planned 15 locally advanced rectal cancer patient . The primary goal define maximally tolerate dose radiotherapy treatment relate acute toxicity , demonstrate preoperative highly conformal IMRT concurrent BV-chemotherapy lead acceptable acute gastrointestinal morbidity . The secondary goal demonstrate treatment modality elicit comparable improve rate T stage downstaging complete response pathologically .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Biopsy proven adenocarcinoma rectum locate 15 cm anal verge flexible endoscopy Patient evaluate surgeon find potential surgical candidate . Since objective response chemoradiation acute toxicity , lesion initially unresectable eligibleâ€”provided surgeon feel , sufficient response , surgery could become feasible Clinical evidence T3 T4 , N0N2 M0 disease . This image study ( transrectal ultrasound MRI ) physical finding ( tether palpation T3 lesion invasion neighbor organ T4 lesion ) Karnofsky Performance Status &gt; 70 Laboratory criterion : Absolute neutrophil count &gt; 1.5 K ; Platelets &gt; 100 K ; Total Bilirubin &lt; 2.0 ; aspartate aminotransferase ( AST ) Alkaline Phosphatase &lt; 2 x upper limit normal ; Creatinine &lt; 1.5 ; Hemoglobin &gt; 8.0 ; international normalize ratio ( INR ) : &lt; 1.5 Hepatitis B ( HBsAg+ ) hepatitis C virus ( antiHCV Ab+ ) carrier status ( antiviral agent allow clinically need ) Informed consent sign Pregnant woman , patient 's age &lt; 20 year &gt; 70 year , patient unable give inform consent Patients past history pelvic radiotherapy Patients malignancy within past 5 year except : skin cancer insitu cervical cancer Patients know allergy/intolerance 5FU , Leucovorin , Oxaliplatin , Bevacizumab Patients prior chemotherapy colorectal cancer Patients grade &gt; 2 peripheral neuropathy Patients condition , opinion treat medical oncologist , render patient unfit 5FU , Leucovorin , Oxaliplatin chemotherapy bevacizumab Patients evidence bleed diathesis coagulopathy , INR &gt; 1.5 Patients require use warfarin sodium &gt; 1 mg Patients active GI ulcer , GI bleeding , active inflammatory bowel disease Patients clinically significant cardiac disease ( e.g. , uncontrolled hypertension [ blood pressure &gt; 160/90 mmHg medication ] , history myocardial infarction unstable angina within 12 month registration ) , New York Heart Association ( NYHA ) Class II great congestive heart failure , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia ) eligible Patients history aneurysm , cerebrovascular accident ( CVA ) arteriovenous malformation Patients arterial thromboembolic event , include transient ischemic attack ( TIA ) , clinically significant peripheral artery disease within 6 month registration Patients serious , nonhealing wound , ulcer , current healing fracture Patients history type fistula ( vesicovaginal , gastrointestinal , etc ) gastrointestinal perforation Patients intraabdominal abscess within 6 month study entry Patients organ transplant Patients placement endorectal stent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>